Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip

Inclusion Criteria: Age 18 to 65, both sexes * Early avascular necrosis of the fem oral head (MRI diagnosis): Ficat and Arlet 0, 1, or 2 (Steinberg stages 0, I, IIA, IIB, or IIC) * Sym ptom atic osteonecrosis with less than 6 months of evolution * Able to provide informed consent, and signed informed consent * Medical health care coverage Exclusion Criteria: * Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control. * Participation in another therapeutic trial in the previous 3 m onths * Stages 3 or m ore (Ficat and Arlet) or III or m ore (Steinberg) of severe fem oral head osteonecrosis,primarily based on diagnosis by im aging (X-Rays, MRI). * Flattening or collapse of the fem oral head (Steinberg stage IV) or articular cartilage collapse at the time of core decompression surgery. * Septic arthritis. * Stress fracture. * Non-osteonecrosis metabolic bone diseases (particularly Paget's disease of bone, osteogenesis imperfecta, primary hyperparathyroidism , fibrous dysplasia monostotic, polyostotic McCune-Albright syndrome\] and osteopetrosis). * Any active bisphosphonate treatment or any history of intravenous (IV) treatment. * History of prior or concurrent diagnosis of HIV-, Hepatitis-B- or Hepatitis-C-infection * Active hepatitis B or hepatitis C infection at the time of screening. * Known allergies to products involved in the production process of MSC. * History of neoplasia or current neoplasia in any organ. * Corticoid or immunosuppressive therapy more than one week in the two months prior to study inclusion * Patients who will require continuous, systemic, high dose corticosteroid therapy (more than 7.5 m g/day) within 6 months after surgery. * Patients who are in active treatment for cancer or blood dyscrasia, or have received chemotherapy, radiotherapy or immunotherapy in the past 2 years. * History of regular alcohol consumption exceeding 2 drinks/day within 6 months of screening and/or history of illicit drug use. * Serum AST (SGO T)/ALT (SGPT) \> 2.5 X (institutional standard range). * MRI-incompatible internal devices (pacemakers, aneurysm clips, etc). * Body mass index (BMI) of 40 kg/m ² or greater. * Patients unable to tolerate general anesthesia defined as an American Society of Anesthesiologists (ASA) criteria of \> 2. * Insulin dependent diabetes * Patients with poorly controlled diabetes mellitus (HbA1C \> 8%), or with peripheral neuropathy, or known concomitant vascular problems. * Patients receiving treatment with hematopoietic growth factors or anti-vasculogenesis or antiangiogenesis treatment. * Traumatic osteonecrosis. * Adult in the care of a guardian (Subject legally protected) * Im possibility to meet at the appointments for the clinical follow up.